Drug-induced liver injury (DILI), a relatively rare condition, is nevertheless a major reason for not approving a drug in development or for removing one already marketed. With a specific diagnostic biomarker lacking, finding elevated serum enzyme [alanine aminotransferase (ALT), aspartate aminotransferase and alkaline phosphatase] activities remains an initial signal for incipient liver injury. Enzyme elevations alone may not be harmful, but if caused by a drug and followed by jaundice (called ‘Hy's law') there is a high possibility of serious DILI. In 1997 several drugs were approved by the Food and Drug Administration (FDA) of the USA that were later withdrawn from the market for serious liver toxicity. New drugs in development are now required to be monitored for liver injury, and the data is to be considered in the approval decision. A program called e-DISH (evaluation of drug-induced serious hepatotoxicity) was introduced in 2004 to aid medical reviewers to select from all subjects studied those few who show nontrivial liver injury and estimate the most likely cause. The threshold of enzyme elevation comprising a warning for possibly serious DILI is uncertain, although generally accepted as 3-5 times the ‘upper limit of normal'. The new direct-acting antiviral agents for treating chronic hepatitis C virus, which often lead to a reduction of elevated ALTs, mandate that a later increase without viral breakthrough be compared to the new on-treatment level of values. The drug may be discontinued or interrupted for evaluation to exclude other possible causes of liver injury. The FDA has approved no drug since 1997 that has been withdrawn later because of serious hepatotoxicity.

Keywords:
Drug-induced liver injury, Causality assessment, e-DISH, Food and Drug Administration, Hyߣs law
1.
Regev A: Drug-induced liver injury and drug development: industry perspective. Semin Liver Dis 2014;34:227-239.
2.
Senior JR: Evolution of the Food and Drug Administration to liver safety assessment for new drugs: current status and challenges. Drug Saf 2014;37(suppl 1):S9-S17.
3.
Zimmerman HJ: Hepatotoxicity: the Adverse Effects of Drugs and Other Chemicals on the Liver, ed 2. Philadelphia, Lipincott, Williams & Wilkins, 1999.
4.
Prati D, Taioli E, Zanella A, Del Torre E, Butelli S, Del Vecchio E, Vianello L, et al: Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002;137:1-10.
5.
Kariv R, Leshno M, Beth-Or A, Strul H, Blendis L, Kokia E, Noff D, et al: Re-evaluation of serum alanine aminotransferase upper normal limits and its modulating factors in large-scale population study. Liver Int 2006;25:445-460.
6.
Lee JK, Shim JH, Lee HC, Lee SH, Kim KM, Lim YS, Chung YH, et al: Estimation of the healthy upper limits for serum alanine aminotransferase in Asian populations with normal liver histology. Hepatology 2010;51:1577-1583.
7.
Food and Drug Administration: Guidance for industry: premarketing risk assessment. 2005. www.fda.gov/downloads/Drugs/Guidance/UCM174090.pdf.
8.
Aithal GP, Watkins PB, Andrade RJ, Larry D, MoloChalasani N, Davern T, Khia M, Takikawa H, Hunt CM, et al: Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 2011;89:806-815.
9.
Pockros PJ: Drugs in development for chronic hepatitis C: a promising future. Expert Opin Biol Ther 2011;11:1611-1622.
10.
Kohli A, Shaffer A, Sherman A, Kottihli S: Treatment of hepatitis C: a systematic review. JAMA 2014;312:631-640.
11.
Temple R: Hy's law: predicting serious hepatotoxicity. Pharmacoepidemiol Drug Saf 2006;5:241-243.
12.
Danan G, Benichou C: Causality assessment of adverse reactions to drugs. I. A novel model based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993;46:1323-1330.
13.
Benichou C, Danan G, Flahault A: Causality assessment of adverse reactions to drugs. II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 1993;46:1331-1336.
14.
Lee WM: Drug-induced acute liver failure. Clin Liv Dis 2013;17:575-586.
15.
Benichou C: Criteria of drug-induced liver disorders: report of an international consensus meeting. J Hepatol 1990;11:272-276.
16.
Food and Drug Administration: Medical product safety information. http://www.fda.gov/medwatch/safety.htm.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.